INTELLECTUAL PROPERTY

OncoLab Diagnostics has secured the following intellectual property rights:

Cancer Diagnosis and Prognosis

A method of identifying an SCLC patient at risk of disease progression comprising determining the RNA-expression of at least one marker selected from a neuroendocrine marker and/or DLL3 in a fraction of a blood sample of said patient which blood fraction is enriched in circulating tumor cells (CTCs), wherein said at least one marker is indicative of the patient’s prognosis.

Publication No.:
WO2020182517A1

Composition and method for determination of CK19 expression

Method for quantitative determination of CK19 mRNA-positive cells in a biological sample.

Publication No.:
WO2007020081, EP1915461, US20140057265, CN101365800

Novel Tumor marker determination

Diagnostic tests for circulating tumor cells in ovarian cancer.

Publication No.:
WO2012123536, CA2830005, EP2686439, US20120238458

Novel Tumor marker determination

Diagnostic tests for circulating tumor cells in breast, ovarian, endometrial and cervical cancer.

Publication No.:
EP2309273, US20140018259

Method and kit for diagnosis of a cancerous disease, method for determining the reaction of a patient to the treatment for a cancerous disease medicament for the prophylaxis or treatment of a cancerous disease

Diagnostic tests for circulating tumor cells in ovarian cancer.

Publication No.:
WO2006018290, EP1786929

Multimarker panel

Diagnostic test for early detection of ovarian cancer based on RNA biomarkers and RNA/protein biomarker models.

Publication No.:
WO2012069659, CA2818976, EP2643477, US20130303400

oncolab_logo_transparent_1246x281

© OncoLab Diagnostics GmbH 2019

OncoLab Diagnostics GmbH
TFZ - Viktor Kaplan-Str. 2, Bldg. E
2700 Wiener Neustadt
Austria